Peer-reviewed veterinary case report
Survival and surgery outcomes in dogs with splenic liposarcoma
By Gower, Krista L A et al.·Published in Journal of the American Veterinary Medical Association·2015·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Splenic liposarcoma in dogs: 13 cases (2002-2012).
- Species:
- dog
Plain-English summary
A group of 13 dogs diagnosed with splenic liposarcoma (a type of cancer in the spleen) showed varying outcomes based on the severity of their condition. Dogs without metastasis (spread of cancer) at the time of surgery had a much longer median survival time of about 767 days, while those with metastasis only survived around 45 days. The grade of the cancer also played a role; dogs with lower-grade tumors lived significantly longer than those with higher-grade tumors. Surgical management was the primary treatment, and the study highlighted the importance of early detection for better outcomes.
People also search for: dog splenic mass treatment · splenic liposarcoma prognosis · dog cancer survival rates
Abstract
OBJECTIVE: To describe the clinical signs, diagnostic findings, surgical management, and outcome in dogs with splenic liposarcoma. DESIGN: Retrospective case series. ANIMALS: 13 client-owned dogs with splenic liposarcoma. PROCEDURES: Medical and pathology records of dogs with a histopathologic diagnosis of splenic liposarcoma from 2002 to 2012 were reviewed for the following data: clinical signs, CBC, biochemical profile, thoracic and abdominal imaging, surgical management, histologic grade, and outcome (local recurrence, distant metastasis, and survival time). Telephone interviews were conducted with referring veterinarians. RESULTS: The median survival time (MST) was 623 days (range, 1 to 1,283 days). In 5 dogs that died of splenic liposarcoma, survival times ranged from 42 to 369 days. Metastasis at the time of surgery was a negative prognostic indicator: the MST was 45 days for dogs with metastasis and 767 days for dogs without metastasis. Dogs with grade 1 splenic liposarcoma had a significantly greater MST (1,009 days), compared with dogs with grade 2 or 3 splenic liposarcoma (MST, 206 and 74 days, respectively). CONCLUSIONS AND CLINICAL RELEVANCE: Results confirmed that splenic liposarcoma is a rare differential diagnosis in dogs with a splenic mass. Survival time was influenced by preoperative clinical stage and histologic grade.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26642134/